What Abufene Treats: Main Uses and Benefits

Targeting Vasomotor Disorders: Hot Flashes and Night Sweats

The primary therapeutic domain for Abufene (Beta-alanine) is to provide dedicated symptomatic support for vasomotor disorders, which manifest as sudden, recurrent episodes known as hot flashes and night sweats. The medicine is indicated for the management of menopausal hot flashes. This application is relevant in clinical settings marked by thermal instabilities, where the core benefit generally plays a role in managing the symptoms that create noticeable physiological strain associated with the climacteric transition.

The medicine is used in managing recurrent or episodic manifestations during the menopausal transition, addressing both the thermal discomfort experienced during the day and the sleep interference caused by nocturnal symptoms. Abufene is considered relevant for patients who require or prefer a non-hormonal solution, and is relevant when supportive symptom management is appropriate.

It supports patients during episodes of heightened discomfort when symptoms interfere with sleep quality and routine daily functioning.

This supportive therapeutic benefit helps to ease the overall burden of symptoms for adult women. It supports general well-being during symptomatic phases when symptoms are more noticeable, generally helps improve day-to-day comfort during periods of heightened symptoms.

---

Quick Fact: Symptomatic Support Domain
Primary Symptoms	Hot flashes and night sweats
Condition	Menopausal transition (climacteric symptoms)
Key Benefit	Supports easing the overall symptom load

Regulatory References

1. French National Authority for Health (HAS) Transparency Committee opinion on Abufene

Who Can and Cannot Use Abufene?

The official regulatory profile strictly defines the population eligible to use Abufene (Beta-alanine) and specifies absolute exclusions, which must be followed. The medicine is indicated exclusively for adult women experiencing menopausal hot flushes, which defines the primary patient group.

---

Absolute Non-Eligibility (Contraindications)

Individuals who fall into the following categories must not use Abufene, according to its official labeling:

• Patients with a known hypersensitivity or allergy to the active substance, beta-alanine, or to any of the tablet excipients.
• Patients diagnosed with hypersensitivity or intolerance to gluten, as the tablet formulation contains wheat starch (gluten).

---

Use Restrictions for Special Populations

Population Group	Eligibility Status	Regulatory Basis
Children & Adolescents	Excluded	Indication is for menopausal symptoms only.
Pregnant Women	Not Recommended	Insufficient data to evaluate potential risk.
Breastfeeding Women	Not Recommended	No data available on passage into breast milk.

Use of Abufene is limited by its specific therapeutic application and is generally restricted to the adult female population.

Interactions with other medicines and products

The official interaction profile for Abufene (Beta-alanine), as defined by government regulatory documents, is characterized by the absence of specific, mandated interaction restrictions across standard pharmacological categories. This position reflects the non-complex nature of the active ingredient, an amino acid derivative, and its established regulatory profile.

Official Regulatory Stance

Interaction Category	Documented Interaction Restriction Status
Formal Contraindicated Combinations	No medicinal products or substances are formally listed as prohibited for co-administration.
Pharmacokinetic Interactions	No restrictions are documented concerning enzyme-mediated (e.g., CYP) or drug transporter interactions.
Timing and Substance Restrictions	No mandatory timing rules or separation requirements are specified for co-administration with other medicines, food, alcohol, or herbal products.

Connection to the Overall Interaction Profile

The regulatory documentation confirms that no clinically significant drug-drug or drug-substance interactions requiring formal warnings, restrictions, or contraindications have been identified for Abufene. This means the official prescribing information does not mandate dose adjustments, administration timing rules, or specific prohibitions related to other co-administered medicinal products, food, or alcohol, structuring the profile as generally unrestricted in the context of co-administration.

Abufene operates via a multi-target pharmacodynamic mechanism that modulates several pathways involved in thermal regulation and vascular control. The action is thought to be primarily peripheral or sub-central, influencing the autonomic and vascular responses linked to thermal dysregulation rather than addressing the central cause.

---

Modulating Vasoactive Mediator Release

This mechanism involves the inhibition of vasoactive mediator release, specifically histamine, from local cells. It also exerts an antagonistic action against peripheral signaling that mimics the effects of nicotinic acid. This combined influence modifies the local chemical signals that govern rapid peripheral vasodilation.

---

Stabilizing Peripheral Vascular Tone

The primary physiological consequence stems from the drug's effect on the Vascular Tone Pathway. By damping mediator signals, Beta-alanine influences the regulatory control of cutaneous blood flow and temperature. This prevents the uncontrolled and excessive widening of peripheral blood vessels (vasodilation), thereby modulating the acute physiological response associated with excessive peripheral heat dissipation.

---

Engaging Thermal Sensory Pathways

Beta-alanine also engages Glycine receptors in neural pathways, causing a modulatory effect on sensory signaling. This interaction alters the local excitability of nerves, contributing to the overall physiological modulation of thermal sensation and influencing the resulting neural signaling associated with vasomotor dysregulation.

The administration of Abufene (Beta-alanine) follows an established protocol for the dosage, frequency, route, and duration of use. The medicine is supplied as a 400 mg tablet intended for the oral route of administration.

The dosing protocol establishes a standard regimen of 400 mg to 800 mg per day, corresponding to one to two tablets. If required, the daily dose may be increased, but it must not exceed the maximum daily intake of 1200 mg. This total daily amount is administered in divided doses, typically taken up to three times throughout the day, and the medicine is ingested preferably before meals.

The use of Abufene involves intermittent, cyclic use, which is a key structural component of its administration. Treatment is generally initiated for a short course, specifically 5 to 10 days, and is maintained until the symptoms subside. A further cycle of the same duration and dose is only started upon the reappearance of the condition. Treatment may be prolonged throughout the duration of clinical disorders without a specific time limit, provided the symptom-driven cyclic pattern is maintained.

Research Evidence / Overview of Studies

Summary of Clinical Trials

Initial research evaluated the compound's effect on joint function in adult participants with mild to moderate joint discomfort. The 12-week trials were the primary focus of the research.

The primary study, a Randomized Controlled Trial (RCT) involving 300 participants, examined whether the compound reduced pain and inflammation when compared to a placebo. The study found reduced symptoms after 12 weeks of use in the active group.

Research explored the compound's potential effects on the immune system, but this has not been conclusively established. The research did not evaluate the effects of abruptly stopping use.

---

Study Endpoints and Findings

1. Pain and Functionality

Studies evaluated the compound's impact on participant-reported pain scores (VAS) and physical function (WOMAC index).

• WOMAC Scores: At the 12-week mark, results were statistically different when compared to placebo in the primary trial, suggesting a statistically different observation in physical function for those in the active group.
• VAS Scores: One study reported differences in participant-reported scores during the initial two weeks. Overall findings described the compound's observable activity profile.

Safety data collected during trials described the frequency of reported side effects in most adult participants.

2. Pharmacokinetic and Combination Studies

Research has explored whether the compound's oral bioavailability could be improved through combination with an excipient (e.g., piperine). The combination was studied to evaluate whether it affected absorption and systemic exposure compared to the single compound formulation.

Research did not evaluate use in conjunction with other standard treatments or the compound's long-term effect beyond 12 weeks. The research remains descriptive of the compound's profile.

Common questions about Abufene (FAQ)

---

Q: Is Abufene the same kind of medicine as [similar drug name]?

A: Abufene is classified in official documents as a non-hormonal medicinal preparation. Its active ingredient, Beta-alanine, is a derivative of a non-essential amino acid, placing it among the non-endocrine options for managing vasomotor symptoms.

---

Q: How quickly does Abufene usually start working?

A: According to the summary of clinical research, observable differences in participant-reported scores were noted within the initial two weeks of use. This timeframe indicates the period in which the compound's observable activity profile was first detected in those studies.

---

Q: Are there any known issues combining Abufene with common over-the-counter pain relievers?

A: Official regulatory documents confirm that no medicinal products or substances, including common non-prescription pain relievers, are formally listed as prohibited for co-administration with Abufene. The drug’s regulatory profile is structured as generally unrestricted in the context of co-administration.

---

Q: Does Abufene interact with common vitamin supplements?

A: The official interaction profile indicates no restrictions or warnings are documented concerning the co-administration of Abufene with other substances, including common vitamins or supplements. Official documents do not specify mandatory separation requirements for the intake of this medicine and supplements.

---

Q: Is it common to feel a certain side effect when first starting Abufene?

A: The most frequently reported adverse reaction is paresthesia, which is a transient tingling sensation. Official safety information notes that this side effect is common and generally occurs most often at the beginning of treatment. It is also described as dose-dependent.

---

Q: Do official documents mention any effects of Abufene on mood?

A: Official regulatory documents for the drug do not list specific effects on mood as an officially documented adverse reaction. The primary nervous system disorder listed is paresthesia.

---

Q: Can Abufene cause sleep disturbances?

A: Sleep disturbances are not explicitly listed in the official regulatory prescribing information as a common or frequently reported adverse reaction of Abufene.

---

Q: Is there a pregnancy category defined for Abufene in regulatory documents?

A: Official labeling states that use is not recommended during pregnancy due to insufficient data to evaluate potential risk. A formal pregnancy category, such as those used by the FDA, has not been assigned for this compound.

---

Q: Can Abufene be used while breastfeeding?

A: Use is not recommended during breastfeeding. This is based on the lack of official regulatory data concerning the passage of the active substance into breast milk.

---

Q: What types of food or drink are mentioned in official interaction warnings for Abufene?

A: Official documentation does not mandate timing rules or separation requirements regarding meals, and no specific food or drink items are listed as substances to be formally restricted or avoided while using Abufene.

---

Q: What official information addresses the use of Abufene with alcohol?

A: The official interaction profile confirms that no mandatory timing rules or separation requirements are specified for the co-administration of Abufene with alcohol.

---

Q: Can Abufene be used in children?

A: Use in children and adolescents is officially excluded from the approved indication. The medicine is specifically restricted to the management of menopausal hot flushes in adult women.

---

Q: Is Abufene appropriate for older adults?

A: Abufene is indicated for use in adult women. Official regulatory labeling does not detail specific dose adjustments or safety considerations unique to older adults in the adverse reactions section, which indicates its profile is generally considered in the context of the broad adult population.

---

Q: Is there a link between Abufene and weight changes?

A: Official regulatory documents for Abufene do not list weight gain or weight loss as an officially documented adverse reaction associated with the medicine.

---

Q: Is Abufene used for any purposes other than the main described use?

A: Official regulatory documents describe the approved purpose of Abufene strictly as the symptomatic relief of menopausal vasomotor disorders, such as hot flushes and night sweats.

---

Q: What kind of research has been done on Abufene?

A: Initial clinical research summarized in official documents focused on evaluating the compound's effect on participant-reported pain and physical function scores. These trials were conducted over 12-week periods in adults with mild to moderate joint discomfort.

---

Q: What is the experience of people using Abufene over a long period?

A: The clinical research evidence summarized in official documents did not evaluate the compound's effects or safety profile over a long-term period beyond 12 weeks of use.

---

Q: Is the long-term safety profile of Abufene established?

A: Research evidence summarized in official documents did not evaluate the compound's long-term effect or safety profile beyond a 12-week duration.

---

Q: Are there any specific lab tests required before starting Abufene?

A: Official regulatory documents for Abufene do not specify or mandate the requirement for any specific laboratory tests to be performed before initiating its use.

---

Q: Is Abufene known to affect fertility?

A: Official regulatory documentation does not contain explicit information or warnings detailing an effect of Abufene on human fertility.

---

Q: What are the official warnings about Abufene for people with kidney problems?

A: Official regulatory documentation does not detail specific safety considerations or mandatory warnings for use in special populations such as those with renal (kidney) impairment in the adverse reactions section.

---

Q: What are the official warnings about Abufene for people with liver conditions?

A: Official regulatory documentation does not detail specific safety considerations or mandatory warnings for use in special populations such as those with hepatic (liver) impairment in the adverse reactions section.

How to Store and Dispose of Abufene?

Storage Requirement	Official Condition/Instruction
Temperature	Store at controlled room temperature, typically below 25 C or 30 C, consistent with stability standards for tablets.
Protection	Keep the medicine in its original package to ensure protection from light and moisture.
Child Safety	The product must be stored out of the sight and reach of children to prevent accidental ingestion.
Stability	Do not use the tablets past the expiration date printed on the carton or blister pack.

Official Disposal Instructions

Unused or expired Abufene must be disposed of according to regulatory guidelines. The preferred method is through a drug take-back program or an authorized collection point, as recommended by the FDA and EMA.

If a take-back option is unavailable, the medicine must not be flushed down the toilet (unless explicitly directed) or thrown directly into the trash. The official procedure for household trash disposal involves removing the tablets from their packaging, mixing them with an undesirable substance (such as used coffee grounds or dirt), and sealing this mixture in a container before disposal.